Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
European Journal of Medical Research|January 28, 2025
Ventilatory variables and computed tomography features in COVID-19 ARDS and non-COVID-19-related ARDS: a prospective observational cohort studyLi-Chung Chiu, Hsin-Hsien Li, Yu-Hsiang Juan, et al.
Biomedical Journal|July 4, 2016
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesionsPing-Chih Hsu, Li-Chung Chiu, Shih-Hong Li, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
American Journal of Cancer Research|October 11, 2023
Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancerChien-Yu Lin, Yun-Tse Chou, Po-Lan Su, et al.
Clinical Medicine Insights. Oncology|July 8, 2025
Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort StudyI-Lin Tsai, Chien-Yu Lin, Po-Lan Su, et al.
Scientific Reports|November 21, 2023
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLCJia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, et al.
Pageof 8